Aetna to pay $86M in arbitration settlement to HCA Healthcare

One of the nation’s largest health insurers, Aetna, will pay $86 million to HCA Healthcare after a lawsuit stemming from 2015 led to an arbitration trial.

The case related to Aetna’s out-of-network benefit payment and administration practices in Florida for service and care provided to members in Aetna’s individual Public Exchange products from 2014 to 2016. According to Aetna, which is now owned by CVS Health, coverage under Aetna’s individual Public Exchange products in the sunshine state was not available until after Dec. 31, 2016, according to a public filing from CVS Health.

According to HCA, Aetna paid too little for services rendered to HCA hospitals that provided emergency room care to out-of-network patients with insurance purchased on the public exchange under the Affordable Care Act. HCA Healthcare is a Tennessee-based hospital and healthcare facilities operator and is a Fortune 500 company.

Last year, HCA Healthcare was awarded $150 million by the trial arbitrator. Aetna’s appeal brought that down to $86 million on March 28, 2019. CVS Health, which completed its $69 billion merger with Aetna at the end of 2018, indicated the settlement amount in its first quarter earnings report.

The lawsuit was not the only trouble for Aetna lately. The health insurer also recently settled out of court with a patient who sued over coverage denial in California and is facing another lawsuit from a Florida hospital over other claims of coverage denial.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

After their proposal for a new American Board of Cardiovascular Medicine was shot down earlier this year, cardiology groups have asked the AMA for some support. "We feel like it's time for us to blaze our own path," one specialist explained. 

The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

American College of Cardiology Board of Governors Chair David E. Winchester, MD, MS, examines the many benefits of working with the American Medical Association House of Delegates to bring about significant change.